Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Bioactivity of AXT107 in nAMD
NCT04746963Phase 2Terminated
- Sponsor
- AsclepiX Therapeutics
- Start
- Feb 2021
- Primary completion
- Oct 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of gersizangitide in neovascular age-related macular degeneration (NVAMD), sponsored by AsclepiX Therapeutics. Started Feb 2021; status: terminated.
02
Drugs
gersizangitide
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04746963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04746963.